Loading...
•
Sep 30, 2024
Aytu BioScience Q1 2025 Earnings Report
Reported positive net income and sixth consecutive quarter of positive adjusted EBITDA.
Key Takeaways
Aytu BioPharma reported a net income of $1.5 million and an adjusted EBITDA of $1.9 million for the first quarter of fiscal year 2025. The company's ADHD portfolio net revenue increased by 1% year-over-year, while the Pediatric Portfolio net revenue increased 54% sequentially. The company is implementing organizational changes and an operating optimization plan to further streamline operations and reduce expenses.
Net income was $1.5 million.
Adjusted EBITDA was $1.9 million.
ADHD Portfolio net revenue increased 1% to $15.3 million.
Pediatric Portfolio net revenue increased 54% sequentially.
Aytu BioScience
Aytu BioScience
Aytu BioScience Revenue by Segment
Revenue by Segment
Pediatric Portfolio Revenue
CapyFin.com Forward Guidance
Aytu expects to further accelerate its profitability goals through continued revenue growth across its product portfolio and continued optimization of its organizational processes with an expectation of reducing its operating expenses by at least $2.0 million annually.